Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel in Relapsed or Refractory Multiple Myeloma
NCT01646762Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Nov 2012
- Primary completion
- Jan 2015
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoint: Overall Response Rate at 3 years. Started Nov 2012; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01646762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01646762.